The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen

被引:684
作者
Sconce, EA
Khan, TI
Wynne, HA
Avery, P
Monkhouse, L
King, BP
Wood, P
Kesteven, P
Daly, AK
Kamali, F [1 ]
机构
[1] Newcastle Univ, Sch Clin & Lab Sci, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[3] Royal Victoria Infirm, Sch Care Elderly, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
关键词
D O I
10.1182/blood-2005-03-1108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype, and body size to warfarin-dose requirements. Studied were 297 patents with stable anticoagulation with a target international normalized ratio (INR) of 2.0 to 3.0. Genetic analyses for CYP2C9 (*2 and *3 alleles) and VKORC1 (- 1639 polymorphism) were performed and venous INR and plasma R- and S-warfarin concentrations determined. The mean warfarin daily dose requirement was highest in CYP2C9 homozygous wild-type patients, compared with those with the variant *2 and *3 alleles (P <.001) and highest in patients with the VKORC1 (position -1639) GG genotype compared with those with the GA genotype and the AA genotype (P <.001). Mean warfarin daily dose requirements fell by 0.5 to 0.7 mg per decade between the ages of 20 to 90 years. Age, height, and CYP2C9 genotype significantly contributed to S-warfarin and total warfarin clearance, whereas only age and body size significantly contributed to R-warfarin clearance. The multivariate regression model including the variables of age, CYP2C9 and VKORC1 genotype, and height produced the best model for estimating warfarin dose (R-2 = 55%). Based upon the data, a new warfarin dosing regimen has been. developed. The validity of the dosing regimen was confirmed in a second cohort of patients on warfarin therapy.
引用
收藏
页码:2329 / 2333
页数:5
相关论文
共 28 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
[Anonymous], 1994, Lancet, V343, P499
[3]   A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial [J].
Beyth, RJ ;
Quinn, L ;
Landefeld, CS .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) :687-695
[4]  
Blackshear JL, 1996, LANCET, V348, P633
[5]   Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity [J].
Bodin, L ;
Verstuyft, C ;
Tregouet, DA ;
Robert, A ;
Dubert, L ;
Funck-Brentano, C ;
Jaillon, P ;
Beaune, P ;
Laurent-Puig, P ;
Becquemont, L ;
Loriot, MA .
BLOOD, 2005, 106 (01) :135-140
[6]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[7]  
Chesebro JH, 1996, ARCH INTERN MED, V156, P409
[8]  
CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V25, P1
[9]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[10]   FLEXIBLE INDUCTION DOSE REGIMEN FOR WARFARIN AND PREDICTION OF MAINTENANCE DOSE [J].
FENNERTY, A ;
DOLBEN, J ;
THOMAS, P ;
BACKHOUSE, G ;
BENTLEY, DP ;
CAMPBELL, IA ;
ROUTLEDGE, PA .
BRITISH MEDICAL JOURNAL, 1984, 288 (6426) :1268-1270